State-of-the-art, multi-modality breast biopsy system slated to be in the market in early 2026 FRANKLIN LAKES, N.J., Jan. 15, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: ...

Anthropic launched Claude for Healthcare on January 11 at the J.P. Morgan Healthcare Conference, introducing HIPAA-ready enterprise tools and consumer health record access a few days after OpenAI's ...

Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of ...

The New York Giants are looking ahead to the 2026 NFL draft and here are some prospects they should scout during Thursday's College Football Playoff games.

Fish & Richardson has elevated 18 new principals, effective January 1, 2026. This accomplished group exemplifies the firm’s ...

St Bartholomew's Hospital and The James Cook University Hospital mark key UK expansion of the company's Phase 2 mCRPC programmeThe patients received Lutetium (177Lu) rhPSMA-10.1 Injections at ...

USPTO Director Squires’s 2025 policies encourage more use of evidence-based SMEDs to challenge patent rejections, especially ...

TRP Diagnostic Pro comes with all-makes software to support routine maintenance, troubleshooting, and mixed fleet repairs.

Clinical laboratories are rallying behind a new bill that could avert steep cuts to Medicare reimbursement for diagnostic ...

(NASDAQ:PROF; TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased ...